Medivir today announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one of Medivir’s preclinical research programs. Under the terms of the agreement, Medivir will receive an undisclosed upfront payment and is eligible to receive multiple undisclosed development and commercial milestones as well as low single-digit royalties on future products.

“We are pleased to see one of our promising preclinical assets finding a new home for further exploration by a very exciting company” said Dr Christina Herder, EVP & COO of Medivir.

“Synthetic lethality as the basis for a cancer drug target discovery engine holds tremendous promise, exemplified by the number of novel context-dependent cancer drug targets we have discovered using this approach in the past few years,” said Barbara Weber, MD, Tango’s President and Chief Executive Officer. “In-licensing this program from Medivir will help us to capitalize on a novel synthetic lethal interaction and accelerate an important program.”